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ImmunotherapyIn considering the challenges of approaches to clinical imaging, we are faced with choices that sometimes are
impacted by rather dogmatic notions about what is a better or worse technology to achieve the most useful
diagnostic image for the patient. For example, is PET or SPECT most useful in imaging any particular disease
dissemination? The dictatorial approach would be to choose PET, all other matters being equal. But is such a
totalitarian attitude toward imaging selection still valid? In the face of new receptor targeted SPECT agents one
must consider the remarkable speciﬁcity and sensitivity of these agents. 99mTc-Tilmanocept is one of the newest
of these agents, now approved for guiding sentinel node biopsy (SLNB) in several solid tumors. Tilmanocept has
a Kd of 3 × 10−11 M, and it speciﬁcity for the CD206 receptor is unlike any other agent to date. This coupledwith
a number of facts, that speciﬁc disease-associated macrophages express this receptor (100 to 150 thousand
receptors), that the receptor has multiple binding sites for tilmanocept (N2 sites per receptor) and that these
receptors are recycled every 15 min to bind more tilmanocept (acting as intracellular “drug compilers” of
tilmanocept into non-degraded vesicles), gives serious pause as to how we select our approaches to diagnostic
imaging. Clinically, the size of SLNs varies greatly, some, anatomically, below the machine resolution of
SPECT. Yet, with tilmanocept targeting, the SLNs are highly visible with macrophages stably accruing adequate
99mTc-tilmanocept counting statistics, as high target-to-background ratios can compensate for spatial resolution
blurring. Importantly, it may be targeted imaging agents per se, again such as tilmanocept, whichmay signiﬁcantly
shrink any perceived chasm between the imaging technologies and anchor the diagnostic considerations in the
targeting and speciﬁcity of the agent rather than any lingering dogma about the hardware as the basis for imaging
approaches. Beyond the elements of imaging applications of these agents is their evolution to therapeutic agents as
well, and even in the neo-logical realmof theranostics. Characteristics of agents such as tilmanocept that exploit the
natural history of diseases with remarkably high speciﬁcity are the expectations for the future of patient- and
disease-centered diagnosis and therapy.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Diagnosis and imaging: setting up the therapeutic continuum
In the preceding 25 years there has evolved a conﬂuence of tumor
biology ideology, nuclear medicine and surgical oncology that has leded on the journal’s Web site
article is available until the
. This is an open access article underto the development of the theory of the “sentinel node” [1–5]. Data
accrued over the intervening years have provided a conﬁrmation of
the sentinel node theory as it relates to the incorporation of sentinel
lymph node detection/biopsy in breast cancer and melanoma patient
outcome in surgical practice [6–14]. Sentinel node theory holds that
there is a predictable anatomical relationship between the immediate
tumor environment and the proximate lymphatic system such that
assessment of this nexus can provide a reliable appraisal of the nodal
disease stage and reduce or eliminate the need for expanded surgery
as this relates to lymphadenectomy, and be equally predictive of nodalthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. A. 99mTc-tilmanocept (Lymphoseek®; Navidea). B. Tilmanocept speciﬁcally binds to CD206.
216 F.O. Cope et al. / Nuclear Medicine and Biology 43 (2016) 215–225status with similar outcomes with regard to any such expatiated
surgery [15–24]. The initial sentinel lymph node biopsy (SLNB) forays
relied on the application of dyes injected into or around the tumorarea, with visual tracing of these dyes, or “chasing” the drainage of the
dyes into the lymphatic ducts and nodes. The ﬂow and adsorption of
the dyes into proximal nodes (and in many cases distal nodes) were
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Fig. 2. Sentinel node discrimination in patient with oral squamous cell carcinoma of the tongue; multiple sentinel nodes are visible 15 min after injection.
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and increased potential for the residence of tumor cells whose deriva-
tion was from the primary tumor [25–31]. This procedure of SLNB was
tested repeatedly in clinical studies and these studies provided valida-
tion of the concept and its positive impact on patient outcome [15–24].
However, other factors altered the clinical landscape of SLNB, in
particular, the adoption of radiolabeled particulates used in other diag-
nostic procedures [32–39]. Although neither blue dyes nor particulate
colloids provided any real speciﬁcity, the combined use of these two
agents has improved SLNB detection reliability to singly employed
dyes or colloids [40–42]. The results of this unlikely amalgam lead
to their use in numerous clinical trials and the expanded adoption of
the SLNB procedure, primarily for breast cancer followed by its use in
melanoma surgery.
In the face of this seeming remedy formitigating someunnecessarily
extensive surgery, the adoption of SLNB in solid tumors other than
melanoma and breast cancer seemed highly likely. However, out of
the evolving SLNB clinical data sets for breast cancer and melanoma,
and especially the experiential data of SLNB in other solid tumors failed
to realize the efﬁcacy found in breast and melanoma surgery, came the
observation that there was a need for an SLN-discriminating agent in
order to thoroughly potentiate the reliability and positive patient out-
come of SLNB. These data strongly suggested that an SLN detection
agent would have to provide true target speciﬁcity such that the
tumor-node axis was more reliably mapped.
The agent that has risen to ﬁll this void is 99mTc-tilmanocept
(Lymphoseek®, Navidea Biopharmaceuticals, Inc.) (Fig. 1A and B).
Tilmanocept functions through a mechanism of action that relies on
its mannose moieties, which bind strongly (as multivalent ligands)
and speciﬁcally to C-type lectin receptors (CD206), which are presentDextran Spine
DTPA
Mannose
Fig. 3. Sentinel node discrimination in patient with breast canceon the surface of macrophages and dendritic cells residing in SLNs. It
is this mechanism of action that gives the tilmanocept platform its
tremendous capability as a diagnostic and SLN detection agent (Figs. 2
and 3). It is now clear from the clinical studies of tilmanocept not only
in breast cancer and melanoma, but in head/neck (oral) squamous cell
carcinoma that such targeting signiﬁcantly reduces the false negative
rate for SLNB (Table 1).
2. Recognition of the imaging-therapeutic axis
As noted, 99mTc-tilmanocept is currently used as a mapping agent
for the identiﬁcation of sentinel lymph nodes in multiple solid tumors.
The approved indications for 99mTc-tilmanocept include guiding SLNB
in clinically node negative breast cancer, melanoma, and oral cavity
squamous cell carcinoma.
In the context of studying and developing 99mTc-tilmanocept, the
cellular biology underlying the diagnostic targeting speciﬁcity is
ineluctably linked to the potential for 99mTc-tilmanocept to be used
as a targeting agent against those diseases studied. The basis for
this eureka moment was the understanding of the pleotropic impact
of the CD206-expressing macrophages not only in the oncology
realm (the tumorigenesis process) but in diseases in general.
Tumor evolution and the necessity of tumor-associated macro-
phages (TAMs) even in the early carcinogenesis process are well
established. It is no coincidence that such macrophages express
CD206, the explicit receptor for Tilmanocept, and that this coincident
convenience is an element of the efﬁcacy of 99mTc-tilmanocept in
SLNB. But the matter is more than this. Macrophages are an integral
process element in a host of other diseases. We now realize that their
integration into disease processes is remarkably complex, with manyr; multiple sentinel nodes are visible 15 min after injection.
Table 1
Sentinel Lymph Node False Negative Rate (FNR) in Head and Neck Squamous
Cell Carcinoma.
1 SLN=sentinel lymph node; non-SLN=non-sentinel lymph node.
2 N/A=Not applicable. False positives were no applicable to the analysis as lymph nodes
did not ﬁt into this category (Nodes cannot both be pathology positive and pathology
negative).
3 The FNR was 0.0256and the exact binomial test of this result against the null hypothesis
H0: FNR ≥ 0.14was statistically signiﬁcant at p= 0.0205. Of the 39 patients with at least 1
pathology-positive lymph node, Lymphoseek detected nodes with positive pathology in
all but 1 patient.
4 Due to a positive (low) FNR of an interim-analysis signiﬁcance level for a 1-sided exact
test of binomial proportion being ≤ 0.02486 after ≥ 38 patients with a pathology-positive
lymph node, the DSMC recommended stopping the trial for efﬁcacy (which ended in ap-
proximately 40 months).
218 F.O. Cope et al. / Nuclear Medicine and Biology 43 (2016) 215–225highly integrated macrophage and disease elements, testifying to the
biologically synchronized transduction of macrophage roles in disease
natural history.
Inmanymaladies, including autoimmune diseases (such asmultiple
sclerosis, diabetes, rheumatoid arthritis (RA), systemic lupus erythema-
tosus (SLE) and Crohn’s disease), infectious diseases (HIV and tubercu-
losis), tumorigenesis, neurodegenerative disorders (dementias) and
cardiovascular disease (vulnerable plaque and atherosclerosis), the
presence of CD206-macrophages becomes an autogenous progression
of the disease state. Table 2 lists a number of these diseases and macro-
phage involvement. This table effectively deﬁnes not only the potential
for diagnostic use of 99mTc-tilmanocept, but also the opportunity for
therapeutic targeting using tilmanocept as the targeting agent.
3. Selected opportunities — exploiting the diagnostic/therapeutic
axis: tilmanocept to Manocepttm
An adaptation of tilmanocept from imaging to therapy is supported by
both in vivo and ex vivo data; we have adapted the nomenclature to
segregate these initiatives: “Manocept” agents that target the sameTable 2
Macrophages in the Natural History of Disease.CD206-macrophagemannose receptor and are derived fromTilmanocept
now represent a therapeutic enterprise. In this vane, we outline below
selected clinical sorties in which there is a validated transition of
tilmanocept diagnostic imaging to Manocept therapeutic targeting.
3.1. Kaposi’s sarcoma (KS)
AIDS-related KS is an aggressive, multifocal, angioproliferative
neoplasm associated with Kaposi's sarcoma herpes virus (HHV8/KSHV)
infection. It involves cutaneous and visceral tissues, with later forms of
disease associated with widespread organ involvement. It is the most
common cancer in patients infected with HIV. Effective antiviral therapy
has produced a decline in the incidence of AIDS related KS, but HIV-
infected individuals still have a 3640-fold greater risk of developing KS
than the uninfected population. In general, no imaging studies have
been able to identify speciﬁc KS-involved tissues, apart from standard
ultrasound and CT imaging, in which therapy-associated changes are
implied to be associated with KS lesion shrinkage.
Inﬂammation appears to play a critical role in tumor development of
HIV-associated KS. Speciﬁcally, emerging data show that KS tumor cells
that co-express various macrophage antigens, especially CD206, the
tilmanocept receptor, become resistant to current anti-viral therapies
used to treat KS and AIDS. Macrophages also are a known source of KS
tumor cell growth factors and substantial evidence suggests that TAMs
represent a reservoir for HIV and its evolved retroviral variants. The
macrophage pool driving these two pathological pathways share a
common element rooted in themacrophages, the CD206humanmacro-
phage mannose receptor. Manocept, as a molecular targeting agent,
binds and entersmacrophages via pinocytosis of holo-CD206, providing
a cell portal for the evaluation of Manocept as a macrophage and KS
targeting agent.
Kaposi's sarcoma lesions are comprised of KS spindle cells infected
with HHV8/KSHV, as well as numerous macrophage antigen-expressing
cells. In a study of over 100 KS lesions we demonstrated that both
skin and visceral forms of KS express the CD206 molecule; CD206
was found on both KS tumor cells and TAMs, allowing the potential
for use of tilmanocept as a tumor-speciﬁc imaging agent capable of
identifying both tumor cells and TAMs in patients with KS (Figs. 4
and 5). The results of imaging in vivo in both HIV+ and HIV− KS
patients suggest the therapeutic potential value of Manocept. The
supra-speciﬁcity of tilmanocept for the KS lesions and the virtual lack
of off-target (non-CD206+) background in vivo are strong evidences
for employing Manocept congeners in KS and other solid tumors as
tumor speciﬁc therapies.
3.2. Rheumatoid arthritis (RA)
Rheumatoid arthritis is a common, chronic, systemic, and progressive
autoimmune disease associated with inﬂammation and pathology
throughout the body, but perhapsmost noticeably in the peripheral joints
of the skeleton (i.e., hands, feet, knees, hips, etc.). In the affected joints, RA
is characterized bymacrophage and lymphocyte inﬁltration, proliferation
of synovial ﬁbroblastic tissue (pannus), and joint destruction. RA causes
joint pain, stiffness and reduced mobility. If not successfully treated,
joint inﬂammation and destruction in RA patients can lead to crippling
.loss of function, severe chronic pain, and disﬁgurement of the joints.
Also, RA patients have signiﬁcantly higher risk of coronary heart
disease including acute myocardial infarction (odds ratio = 3.17).
Patients with uncontrolled RA may also suffer a reduction of
3–10 years in their life expectancies. RA can strike anyone at any
age, but is diagnosed most frequently in women in their 40s and
50s. Worldwide, about one adult in every 200 has RA. In the United
States, approximately 1.3 million adults have RA. RA is a chronic dis-
ease and the prevalence of RA increases with age. Because of aging
demographics in the United States and elsewhere, the number of pa-
tients with RA and the burden of RA on society are expected to
Fig. 4.CD206 expresses on both Kaposi’s sarcoma spindle cells and associatedmacrophages (A, Nuclear stain DAPI; B, Anti-CD206; C, Anti-LANA/HHV8; D, Anti-CD68macrophagemarker;
E, merged images).
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rent and growing need to manage RA patients more effectively to
limit the morbidity and mortality caused by RA.
While many types of cells, including T-cells, B-cells, dendritic cells,
and activated synovial ﬁbroblasts, contribute signiﬁcantly to the estab-
lishment and maintenance of RA, macrophages play a critical role in
RA pathogenesis. They produce most of the TNFα that drives and per-
petuates the inﬂammatory cycle in RA. In the synovial sub-lining of a
joint affected by RA, macrophages are the dominant cell type. In the in-
ﬂamed joint as a whole, macrophages in RA patients make up at least
30%–40% of all cells. Furthermore, macrophages participate directly in
the destruction of bone and cartilage. Activated macrophage popula-
tions and synoviocytes are the predominant cell types at the interface
between pannus and cartilage and secrete destructive proteases in
abundance. As a result, itmaynot be surprising that synovialmacrophage
numbers – but not the numbers of other immune cell types – correlate
with radiographically determined joint destruction in RA. While macro-
phages may play a role in other pathologies that cause joint pain and in-
ﬂammation, the degree to which macrophages are involved in the
pathological process of RA and the sheermass or volume ofmacrophages
that inﬁltrate the joints inﬂamed due to RA differentiate RA from other
rheumatic diseases. Therefore, detection of the density or numbers of
macrophages in inﬂamed joints may permit differentiation of patients
with RA from those with other causes of arthritis. In addition, it is
known that the RA pathology begins signiﬁcantly before, perhaps
years before, the onset of symptoms (i.e., joint pain and inﬂammation)
andwell before the beginning of bone destruction.Macrophage inﬁltra-
tion of synovial tissues precedes development of RA clinical signs in an-
imal studies. In humans, macrophage inﬁltrates in synovial tissues are
present when RA patients ﬁrst develop clinical symptoms. Therefore,
detection of the density or numbers of macrophages in inﬂamed joints
may facilitate more sensitive and speciﬁc identiﬁcation of RA patients
as soon as they present with symptoms and early in the course of
their illnesses when disease-modifying anti-rheumatic drugs
(DMARDs) are likely to be most effective.
Below are select data from studies using tilmanocept as an imaging
agent for synovial macrophages in the inﬂamed joints of RA patients
and in animal models. We investigated CD206 expression and
tilmanocept binding to synovial macrophages in an anti-type II collagen
monoclonal antibody induced mouse model of RA. Male 8-week-oldDba1 mice (n = 8) were injected intraperitoneally (IP) with 1.5 mg
Athrogen-CIA arthrogenic ﬁve monoclonal antibody cocktail to Type II
collagen followed in three days by an IP injection with E. coli 0111:B4
lipopolysaccharide. Control mice (n = 4) were injected with
phosphate-buffered saline. Evidence of arthritis (joint swelling and
redness) developed in 5–6 days, and the severity of arthritis was
scored for each limb daily. On days 9 or 11, mice were imaged
1–2 h after they had received an intravenous injection of ﬂuorescent
Cy3-tilmanocept. The mice were then euthanized followed by limb
dissection and reimaging. The primary result of this experiment
was that Cy3-tilmanocept administered intravenously localized to
synovial macrophages in the affected joints of arthritic mice but
not control mice (Fig. 6).
Ex vivo experiments showed speciﬁc binding of Cy3-tilmanocept to
human synovial macrophages obtained in samples from patients with
active RA undergoing therapeutic surgical procedures (Fig. 3). For
these studies, RA patients were recruited through approved institution-
al review board protocols. Flash-frozen synovial tissue was sectioned to
4 μmonto glass slides for immunohistochemistry. Slideswere incubated
with DAPI nuclear stain (blue), an anti-CD206 antibody and/or Cy3-
tilmanocept (red). Bound anti-CD206 antibody was visualized with a
secondary antibody conjugated with Alexa Fluor 647 (green). Images
were obtained using a Zeiss ﬂuorescent microscope and merged to
show co-localization. It is important to note that, ﬁrst, human synovial
macrophages from human RA patients abundantly express CD206, and
(second) Cy3-tilmanocept binds to human synovial macrophages
and co-localizes with CD206. Finally (third), CD206-expressing macro-
phages are a highly abundant cell type in RA synovia. The speciﬁcity
of Cy3-tilmanocept binding to synovial macrophages was further
demonstrated by pre-incubating with a tenfold excess of tilmanocept
that had not been conjugated with Cy3. Pre-incubation with un-
conjugated tilmanocept completely abolished Cy3-tilmanocept
binding (Fig. 7).
In order to provide perspective around the speciﬁcity of
tilmanocept binding/uptake into RA synovial macrophages, addi-
tional experiments performed with synovial tissues obtained from
joints of patients with osteoarthritis and from healthy controls (ob-
tained from a tissue bank), provided results showing that Cy3-
tilmanocept binding was much greater in synovial tissues from RA
patients than it was in similar tissues obtained from patients with
Fig. 5. Patient injected subcutaneously with Tc99m-Tilmanocept (50 μg; 2.0 mCi) and
imaged 4 h post-injection; SPECT WHOLE BODY SCAN: Injection site lower left leg; KS
lesions match tracings of leg lesions; TC99m-tilmanocept localizes in KS chain linked by
lymphatic ducts; localizes in (KS+?) inguinal nodes; left of nodes in image is bladder.
mouse
Control 
mouse
RA
Fig. 6.Mice were imaged in the IVIS (in vivo imaging system) to measure Cy-3 levels. In
these ex vivo images, the limbs were detached and the skin was removed before imaging.
On the bottom you can see the enhanced signal in the RA mice knees. The values are
statistically signiﬁcant when quantitated.
Fig. 7. Staining of synovial tissue frozen sections from a patientwith Rheumatoid arthritis.
Sections were stained with 4',6‐diamidino‐2‐phenylindole, BLUE (DAPI = DNA) and
Cy3‐tilmanocept–RED/PINK (CD206) and examined under ﬂuorescence microscopy.
220 F.O. Cope et al. / Nuclear Medicine and Biology 43 (2016) 215–225osteoarthritis or healthy controls. It is well known that osteoarthritic
joints contain macrophage inﬁltrates; however, in osteoarthritis, sy-
novial macrophages are less numerous than in RA and as this exper-
iment shows, synovial macrophages in osteoarthritis produce much
less CD206 (Fig. 8).
Similar to KS, the speciﬁcity of tilmanocept for the RA loci and the
virtual lack of off-target (non-CD206+) background reactivity provide
strong supportive evidence for employing Manocept congeners in
RA therapies.
3.3. Tuberculosis (TB)
Mycobacterium tuberculosis (Mtb) is an airborne pathogen that infects
the lungs and then can disseminate throughout the body. Mtb is spread
when an individual with symptomatic or active TB coughs, creating an
Mtb-rich aerosol that canbe inhaled into the lungs of previouslyuninfected
persons. Alveolar macrophages recognize Mtb by various means but im-
portantly through interactions between the mannose caps on the Mtbcoat molecule, mannosyslated lipoarabinomannan (ManLAM), and
CD206. The interaction between ManLAM and CD206 is important
because it alters phagosome trafﬁcking, inhibiting fusion of the Mtb-
containing phagosome with lysosomes, and allowing Mtb to survive
and replicate in these cells. The infected alveolar macrophage then
secretes various cytokines that attract additional macrophages and
various other immune cells. Mtb replication and dissemination com-
bined with the accumulation of various immune cells lead to a robust
systemic immune response and the early formation of a granuloma.
The granuloma (granulomatous pulmonary Mtb) is comprised of T
and B lymphocytes surrounding a ﬁbrous cuff. Within the ﬁbrous cuff
there are macrophages (both infected and uninfected) and some
Fig. 8.We then examined CD206 andManocept in synovial tissue. In themerged image, you can clearly see the co-localization of CD206 andManocept. Healthy and osteoarthritis synovial
tissue samples were negative for both.
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perturbed, perhaps in response to stimuli from the Mtb, causing them
to further differentiate into foam cells containing lipid micro-droplets.
The granuloma sequesters Mtb and prevents it from spreading to other
parts of the body. However, Mtb can persist in a metabolically quiescent
state for years or decades in granulomas. The largemajority of individuals
who become infected with Mtb do not exhibit symptoms, having their
Mtb sequestered in granulomas. Such asymptomatic persons are said to
have latent TB infections (LTBI). Unfortunately over time, there is risk
that a granuloma can progress, with the patient developing active TB. In
active TB, the granuloma enlarges with a necrotic center comprised of
Mtb cells and a lipid rich material derived from the cellular debris of
dead foam cells, which is called caseumdue to an appearance resemblingFig. 9. Human monocyte-derived macrophages in monolayer culture that make up the comp
internalized by macrophages. The infected cells were exposed to tilmanocept-Cy3 and then anmilky cheese. In time, the granuloma may rupture releasing Mtb and
necrotic debris into the patient’s airway, causing coughing that spreads
the infection to other people. If a person with active TB is not treated,
on average they will transmit Mtb to 10–15 people per year. A latently
infected person without co-morbidities such as AIDS or diabetes has a
5%–10% chance of developing active TB over their lifetime. It is estimated
that one third of the world’s population is latently infected with Mtb.
Our recent data show (Fig. 9) that the infection ofmacrophageswith
Mtb does not downregulate the synthesis and expression of CD206, nor
does infection abrogate the uptake of tilmanocept via CD206 and its
accrual intracellularly.
These data are, again, notable evidence for the use of a Manocept
therapeutic congener for the treatment of Mtb and drug resistantonents of the TB granulomas are infected with a GFP-expressingM. tuberculosis which is
alyzed by confocal microscopy.
Fig. 10. Cy3-Tilmanocept targets macrophages in arteries with atherosclerosis; ﬁgure shows co-localization of CD206 antibodies (blue), Cy-3-tilmanocept (red) and CD163 (green)
macrophage markers in arteries of SIV-infected macaque monkeys.
222 F.O. Cope et al. / Nuclear Medicine and Biology 43 (2016) 215–225Mtb to the extent that we believe these data suggest that the biology
of the granuloma is now made vulnerable to attack using many
congener strategies.
3.4. Cardiovascular disease
Atherosclerosis is a chronic inﬂammatory syndrome that develops
slowly in the walls of arteries over the course of many years or decades.
The initiation and progression of atherosclerosis involve interactions
between plasma lipoproteins, cytokines extracellularmatrix, inﬂamma-
tory signaling molecules and several cell types including macrophages.
The primary lesion of atherosclerosis is the atherosclerotic plaque.
Atherosclerotic plaques can expand into the lumen of an artery, even-
tually impacting and diminishing the ﬂow of blood. This impairment
of blood ﬂow can result in angina pectoris, which is painful and debili-
tating. Alternatively, atherosclerosis can progress to an advanced state
without producing symptoms. Eventually, an atherosclerotic plaque
can rupture causing the internal contents of the plaque to come
into contact with the blood, thereby initiating thrombus (i.e., clot) for-
mation. These clots can lead to ischemic events that manifest as myo-
cardial infarctions, sudden cardiac deaths or strokes. For a tragically
large proportion of patients, experiencing one of these potentially cata-
strophic and/or lethal events is the ﬁrst observed symptomexperienced
by a patientwith advanced atherosclerosis. To prevent these potentially
catastrophic plaque rupture associated events, it is necessary to identify
patients with atherosclerotic plaques that are at high risk of near term
rupture so that appropriate intensive rupture preventing therapeutic
interventions can be administered.
Autopsies performed on people who have died as a result of infarc-
tions caused by ruptures of atherosclerotic plaques have identiﬁed the
relevant ruptured plaques, which are termed the “culprit lesions.” To
identify individuals at high-risk of impending plaque rupture, athero-
sclerotic plaques that most closely resemble culprit plaques but which
have not yet ruptured have been identiﬁed. These culprit-resembling
plaques are termed “vulnerable plaques.” Vulnerable plaques have
morphological features and internal compositions that differentiate
them from other atherosclerotic plaques (i.e., stable plaques). These
differentiating features include the presence of large necrotic coresassociated with a lipid pool and a thin (b65 micron) ﬁbrous cap. This
type of vulnerable plaque is also referred to as a thin cap ﬁbroatheroma
(TCFA). TCFA and culprit plaques are not typically highly calciﬁed, but
may display evidence of nascent calciﬁcation that is not yet extensive.
Interestingly, despite their relatively large sizes, TCFA most commonly
does not cause severe narrowing of the lumen of the arteries in which
they occur. Instead TCFA is frequently associated with remodeling of
their arterial walls that expands their arterial lumens to accommodate
their relatively large volumes.
Macrophages contribute a key and evolving role at each stage of the
pathological development of atherosclerosis. Following an injury to
the arterial endothelium, low density lipoproteins (LDLs) invade the
endothelium and become oxidized, initiating an inﬂammatory response
that attracts monocytes. These monocytes ingest the oxidized LDLs and
becomemacrophage “foam cells” that further propagate the inﬂamma-
tory response by secreting pro-inﬂammatory cytokines. Eventually, the
foam cells die or undergo apoptosis creating the lipid rich necrotic core
of vulnerable plaque. The necrotic core further attracts macrophages.
Narula et al. examined atherosclerotic plaques from patients who died
suddenly [132]. They observed that an increase in the number of
inﬁltrating macrophages was a key discriminator between TCFA and
stable plaques. Importantly, Tahara et al. also examined atherosclerotic
plaques from patients that had suffered sudden cardiac death [133].
They conﬁrmed Narula’s ﬁndings of increased macrophages in TCFA.
In addition, immunohistochemical analyses on the plaques found that
large proportions of macrophages in TCFA, but not in stable thick
capped plaques, conﬁrmed positive expression of CD206, the macro-
phage mannose receptor and the speciﬁc target for 99mTc-tilmanocept
binding, and CD163, both markers for alternative, M2, macrophage
activation [29–32]. These results suggest that Tc-tilmanocept will bind
to abundant macrophage targets in TCFA and that CD206 imaging
results can differentiate TCFA from stable atherosclerotic plaques.
Macrophages can be activated to differentiate into various gene
expression phenotypeswhen stimulated by various combinations of cy-
tokines and their local environment. Macrophages can be activated to a
pro-inﬂammatory, M1, phenotype, or anti-inﬂammatory, M2a, M2b,
and M2c, phenotypes. Early in the development of atherosclerosis, M1
macrophages predominate in atherosclerotic plaques, with foam cells
223F.O. Cope et al. / Nuclear Medicine and Biology 43 (2016) 215–225expressing many pro-inﬂammatory cytokines characteristic of an M1
phenotype. M2a and M2c express high levels of CD206. M2c macro-
phages are particularly interesting because they accumulate in areas
where apoptotic cells are present. The necrotic cores of vulnerable
atherosclerotic plaques result largely from the apoptosis of foam cells
and as such, would be expected to attract M2c macrophages. M2c
macrophages abundantly express CD163 in addition to CD206.
These observations are consistent with our approach to exploiting
this cardiovascular disease natural history with Manocept congeners
for both imaging and therapy. Our ex vivo data showing both the
expression of CD206 and the localization of ﬂuorescent Manocept in
the coronary arteries on this CD206 are strong evidence for the axis
initiative in this disease (Fig. 10).
4. Conclusions
In the wake of innovation, tilmanocept (and as Manocept) is self-
transforming from a powerful diagnostic/imaging agent in cancer stag-
ing procedures into a potential multi-application molecule for
diagnosis and treatment of an array of diseases. It has displayed its effec-
tiveness in applications with regards to SLNB, much due to its unique
structure and targeting. As a non-particulate, small molecular size, re-
ceptor targeted (CD206) molecule with the ability to interchange not
only radionuclides but also lethal or biological modiﬁer molecules,
tilmanocept/Manocept has great potential for targeting macrophage
mediated diseases and delivering an effective, concentrated dose for
purposes of diagnosis or treatment. As Manocept continues to generate
clinically relevant data for future applications in immunotherapies for
KS (and other solid tumors), RA, TB, and cardiovascular disease, one
thing remains clear: the selection of this approach, targeting CD206,
appears to provide encouraging results with inter-disease consistency
and reliability on the this immuno-biological strategy [43–139].
References
[1] Gould EA, Winship T, Philbin PH, Kerr HH. Observations on a "sentinel node" in
cancer of the parotid. Cancer 1960;13:77–8.
[2] Cabanas RM. An approach for the treatment of penile carcinoma. Cancer 1977;39:
456–66 [PMID 837331].
[3] Morton DL, Wen DR, Wong JH, Econmou JS, Cagle LA, Storm FK, et al. Technical de-
tails of intraoperative lymphatic mapping for early stage melanoma. Arch Surg
1992;127:392–9.
[4] Krag DN,Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of
the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993;2:
335–9.
[5] Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel
lymphadenectomy for breast cancer. Ann Surg 1994;220:391–8.
[6] Giuliano AE. Mapping a pathway for axillary staging: a personal perspective on the
current status of sentinel lymph node dissection for breast cancer. Arch Surg 1999;
134:195–9.
[7] Turner RR, Ollila DW, Krasne DL, Giuliano AE. Histopathologic validation of the
sentinel lymph node hypothesis for breast carcinoma. Ann Surg 1997;226:271–8.
[8] Hsueh EC, Turner RR, Glass EC, Brenner RJ, BrennanMB, Giuliano AE. Sentinel node
biopsy in breast cancer. J Am Coll Surg 1999;189:207–13.
[9] Giuliano AE, Haigh PI, Brennan MB, Hansen NM, Kelley MC, Ye W, et al. Prospective
observational study of sentinel lymphadenectomy without further axillary dissection
in patients with sentinel node-negative breast cancer. J Clin Oncol 2000;18:2553–9.
[10] Tanis PJ, Nieweg OE, Valdés Olmos RA, Th Rutgers EJ, Kroon BB. History of sentinel
node and validation of the technique. Breast Cancer Res 2001;3(2):109–12.
[11] Krag DN. Is axillary dissection needed when the sentinel node is positive? Yes!
J Surg Oncol 2008;97(3):197–8. http://dx.doi.org/10.1002/jso.20850.
[12] Sadeghi R, Asadi M, Treglia G, Zakavi SR, Fattahi A, Krag DN. Determining axillary
concordance rate for different injection locations in sentinel node mapping of
breast cancer: how ambitious can we get? Breast Cancer Res Treat 2014;146(1):
231–2. http://dx.doi.org/10.1007/s10549-014-2938-2 [PubMed PMID: 24878987].
[13] Calhoun BC, Chambers K, Flippo-Morton T, Livasy CA, Armstrong III EJ, Symanowski JT,
et al. Breast cancer detection in axillary sentinel lymph nodes: the impact of the
method of pathologic examination. Hum Pathol 2014;45(12):2497–501. http://dx.
doi.org/10.1016/j.humpath.2014.09.004 [Epub 2014Oct 2. PubMed PMID: 25449631].
[14] Pesek S, Ashikaga T, Krag LE, Krag D. The false-negative rate of sentinel node biopsy
in patients with breast cancer: a meta-analysis. World J Surg 2012;36(9):2239–51.
http://dx.doi.org/10.1007/s00268-012-1623-z [PubMed PMID: 22569745; PubMed
Central PMCID: PMC3469260].
[15] Parrett BM, Kashani-Sabet M, Singer MI, Li R, Thummala S, Fadaki N, et al. Long-
term prognosis and signiﬁcance of the sentinel lymph node in head and neckmelanoma. Otolaryngol Head Neck Surg 2012;147(4):699–706 [Epub 2012 Apr
24. PubMed PMID: 22535913].
[16] Layﬁeld DM, Agrawal A, Roche H, Cutress RI. Intraoperative assessment of sentinel
lymph nodes in breast cancer. Br J Surg 2011;98(1):4–17. http://dx.doi.org/10.
1002/bjs.7229 [Epub 2010 Sep 1. Review. PubMed PMID: 20812233].
[17] Holloway CM, Easson A, Escallon J, Leong WL, Quan ML, Reedjik M, et al. Technol-
ogy as a force for improved diagnosis and treatment of breast disease. Can J Surg
2010;53(4):268–77 [Review. PubMed PMID: 20646402; PubMed Central PMCID:
PMC2912014].
[18] Clark RR, Shaw-Dunn J, Soutar DS. A cadaveric study of auricular lymphatics and
implications for sentinel lymph node biopsy. Clin Anat 2010;23(7):792–7. http://
dx.doi.org/10.1002/ca.21015 [PubMed PMID: 20641070].
[19] Pajares M, Freire JM, Moreno P, Utor A, Tocino A, Alonso E. Evaluation of the quality
of the sentinel lymph node biopsy procedure in patients with breast cancer. Rev
Esp Med Nucl 2010;29(5):236–40. http://dx.doi.org/10.1016/j.remn.2010.05.003
[Epub 2010 Jul 16. Spanish. PubMed PMID: 20637527].
[20] Wells BJ, Najjar H, Wright FC, Holloway CM, Fraser N, McCready D, et al. Measuring
the quality of sentinel lymph node biopsy in breast cancer using newly developed
quality indicators: a feasibility study. Ann Surg Oncol 2011;18(1):78–85. http://dx.
doi.org/10.1245/s10434-010-1190-1 [PubMed PMID: 20625839].
[21] Piñero A. Present and future of sentinel lymph node biopsy in breast cancer staging.
Clin Transl Oncol 2010;12(7):457–8. http://dx.doi.org/10.1007/s12094-010-0536-2
[PubMed PMID: 20615820].
[22] Shen J, Wallace AM, Bouvet M. The role of sentinel lymph node biopsy for melano-
ma. Semin Oncol 2002;29(4):341–52 [Review. PubMed PMID: 12170437].
[23] Davis KG, Schriver JP, Waddell B. Implementation of sentinel lymph node biopsy
for breast cancer by surgeons in the Department of Defense. Am J Surg 2002;
184(2):94–6 [PubMed PMID: 12169350].
[24] Tuttle TM, Zogakis TG, Dunst CM, Zera RT, Singletary SE. A review of technical
aspects of sentinel lymph node identiﬁcation for breast cancer. J Am Coll Surg
2002;195(2):261–8 [Review. PubMed PMID: 12168974].
[25] Giménez J, Botella-Estrada R, Hernández D, Carbonell M, Martínez MA, Guillén C,
et al. Anaphylaxis after peritumoral injection of sulphan blue 1% for identiﬁcation
of the sentinel node in lymphatic mapping of the breast. Eur J Surg 2001;
167(12):921–3 [PubMed PMID: 11841084].
[26] Li X, Wang J, Zhou Z. Experimental study of sentinel lymph node biopsy in thyroid
by using three kinds of vital dyes at different concentration and dose. Lin Chung Er
Bi Yan Hou Tou Jing Wai Ke Za Zhi 2007;21(21):988–90 [Chinese. PubMed PMID:
18309656].
[27] Zakaria S, Hoskin TL, Degnim AC. Safety and technical success of methylene blue
dye for lymphatic mapping in breast cancer. Am J Surg 2008;196(2):228–33.
http://dx.doi.org/10.1016/j.amjsurg.2007.08.060 [PubMed PMID: 18367146].
[28] Liang MI, Carson III WE. Biphasic anaphylactic reaction to blue dye during sen-
tinel lymph node biopsy. World J Surg Oncol 2008;6:79. http://dx.doi.org/10.
1186/1477-7819-6-79 [PubMed PMID: 18655732; PubMed Central PMCID:
PMC2518154].
[29] Bühler HS, Rojas PH, Cayazzo MD, Cunill CE, Vesperinas AG, Hamilton SJ. Exclusive
use of blue dye to detect sentinel lymph nodes in breast cancer. RevMed Chil 2008;
136(8):1015–20 [doi: /S0034-98872008000800008. Epub 2008 Oct 7. Spanish.
PubMed PMID: 18949185].
[30] Teknos D, Ramcharan A, Oluwole SF. Pulmonary edema associated with methylene
blue dye administration during sentinel lymph node biopsy. J Natl Med Assoc
2008;100(12):1483–4 [PubMed PMID: 19110921].
[31] East JM, Valentine CS, Kanchev E, Blake GO. Sentinel lymph node biopsy for breast
cancer usingmethylenebluedyemanifests a short learning curve among experienced
surgeons: a prospective tabular cumulative sum(CUSUM)analysis. BMCSurg 2009;9:
2. http://dx.doi.org/10.1186/1471-2482-9-2 [PubMed PMID: 19173714; PubMed
Central PMCID: PMC2640353].
[32] Gershenwald JE, Tseng CH, Thompson W, Mansﬁeld PF, Lee JE, Bouvet M, et al.
Improved sentinel lymph node localization in patients with primary melanoma with
the use of radiolabeled colloid. Surgery 1998;124(2):203–10 [PubMed PMID: 9706139].
[33] Wengenmair H, Kopp J, Vogt H, Wawroschek F, Gröber S, Dorn R, et al. Sentinel
lymph node diagnosis in prostatic carcinoma: II. Biokinetics and dosimetry of
99mTc-Nanocolloid after intraprostatic injection. Nuklearmedizin 2002;41(2):
102–7 [German. PubMed PMID: 11989296].
[34] Rasgon BM. Use of low-dose technetium Tc 99 m sulfur colloid to locate sentinel
lymph nodes in melanoma of the head and neck: preliminary study. Laryngoscope
2001;111(8):1366–72 [PubMed PMID: 11568570].
[35] Tafra L, Chua AN, Ng PC, Aycock D, Swanson M, Lannin D. Filtered versus unﬁl-
tered technetium sulfur colloid in lymphatic mapping: a signiﬁcant variable in
a pig model. Ann Surg Oncol 1999;6(1):83–7 [PubMed PMID: 10030419].
[36] Pijpers R, Borgstein PJ, Meijer S, Krag DN, Hoekstra OS, Greuter HN, et al. Transport
and retention of colloidal tracers in regional lymphoscintigraphy in melanoma: in-
ﬂuence on lymphatic mapping and sentinel node biopsy. Melanoma Res 1998;
8(5):413–8 [PubMed PMID: 9835454].
[37] Bartolomei M, Testori A, Chinol M, Gennari R, De Cicco C, Leonardi L, et al. Sentinel
node localization in cutaneous melanoma: lymphoscintigraphy with colloids and
antibody fragments versus blue dye mapping. Eur J Nucl Med 1998;25(11):
1489–94 [PubMed PMID: 9799344].
[38] LiptayMJ,D'amicoTA,NwoguC,DemmyTL,WangXF,GuL, et al. Intraoperative sentinel
node mapping with technitium-99 in lung cancer: results of CALGB 140203
multicenter phase II trial. J Thorac Oncol 2009;4(2):198–202. http://dx.doi.
org/10.1097/JTO.0b013e318194a2c3 [PubMed PMID: 19179896].
[39] Wallace AM, Vera DR, Stadalnik RC. Blue dye and 99mTc-labeled human serum al-
bumin: sentinel node detection by magic bullets? J Nucl Med 1999;40(7):1149–50
[PubMed PMID: 10405135].
224 F.O. Cope et al. / Nuclear Medicine and Biology 43 (2016) 215–225[40] Stolier A. Breast lymphatic mapping using blue dye and radiocolloid. J Am Coll Surg
2002;194(5):681 [author reply 681-3. PubMed PMID: 12022613].
[41] Tafra L, Lannin DR, SwansonMS, Van Eyk JJ, Verbanac KM, Chua AN, et al. Multicen-
ter trial of sentinel node biopsy for breast cancer using both technetium sulfur col-
loid and isosulfan blue dye. Ann Surg 2001;233(1):51–9 [PubMed PMID:
11141225; PubMed Central PMCID: PMC1421166].
[42] van der Ent FW, Kengen RA, van der Pol HA, Hoofwijk AG. Sentinel node biopsy in
70 unselected patients with breast cancer: increased feasibility by using 10 mCi
radiocolloid in combination with a blue dye tracer. Eur J Surg Oncol 1999;25(1):
24–9 [PubMed PMID: 10188850].
[43] Amr D, Broderick-Villa G, Haigh PI, Guenther JM, DiFronzo LA. Adverse drug reac-
tions during lymphatic mapping and sentinel lymph node biopsy for solid neo-
plasms. Am Surg 2005;71(9):720–4 [PubMed PMID: 16468505].
[44] Gipponi M. Clinical applications of sentinel lymph-node biopsy for the staging and
treatment of solid neoplasms. Minerva Chir 2005;60(4):217–33 [Review. English,
Italian. PubMed PMID: 16166921].
[45] Alex JC. The application of sentinel node radiolocalization to solid tumors of the
head and neck: a 10-year experience. Laryngoscope 2004;114(1):2–19 [Review.
PubMed PMID: 14709988].
[46] Krag DN, Weaver DL. Pathological and molecular assessment of sentinel lymph nodes
in solid tumors. Semin Oncol 2002;29(3):274–9 [Review. PubMed PMID: 12063680].
[47] Gershenwald JE, Coit DG, Sondak VK, Thompson JF. The challenge of deﬁning
guidelines for sentinel lymph node biopsy in patients with thin primary cutaneous
melanomas. Ann Surg Oncol 2012;19(11):3301–3. http://dx.doi.org/10.1245/
s10434-012-2562-5 [PubMed PMID: 22868918].
[48] Winter A, Vogt C, Weckermann D, Wawroschek F. [Complications of pelvic lymph-
adenectomy in clinically localised prostate cancer: different techniques in compar-
ison and dependency on the number of removed lymph nodes]. Aktuelle Urol
2011;42(3):179–83. http://dx.doi.org/10.1055/s-0031-1271389. Epub 2011 Mar
15. German [PubMed PMID: 21409742].
[49] Schurr PG, Behnke S, Kaiﬁ JT, Bogoevski D, Link B, Mann O, et al. Central mesenteric
lymph node BER-Ep4+ cells in colorectal cancer: challenge to sentinel node con-
cept? Dig Surg 2007;24(1):19–27 [Epub 2007 Mar 16. PubMed PMID: 17369677].
[50] Wallace AM, Hoh CK, Vera DR, Darrah DD, Schulteis G. Lymphoseek: a molecular
radiopharmaceutical for sentinel node detection. Ann Surg Oncol 2003;10(5):
531–8 [PubMed PMID: 12794019].
[51] Baker JL, Pu M, Tokin CA, Hoh CK, Vera DR, Messer K, et al. Comparison of [(99 m)
Tc] tilmanocept and ﬁltered [(99 m) Tc] sulfur colloid for identiﬁcation of SLNs in
breast cancer patients. Ann Surg Oncol 2015;22(1):40–5. http://dx.doi.org/10.
1245/s10434-014-3892-2 [Epub 2014 Jul 29. PubMed PMID: 25069859; PubMed
Central PMCID: PMC4273083].
[52] Wallace AM, Han LK, Povoski SP, Deck K, Schneebaum S, Hall NC, et al. Comparative
evaluation of [(99 m) Tc] tilmanocept for sentinel lymph node mapping in breast
cancer patients: results of two phase 3 trials. Ann Surg Oncol 2013;20(8):
2590–9. http://dx.doi.org/10.1245/s10434-013-2887-8 [Epub 2013 Mar 17.
PubMed PMID: 23504141; PubMed Central PMCID: PMC3705144].
[53] SondakVK, KingDW,Zager JS, SchneebaumS, Kim J, Leong SP, et al. Combined analysis
of phase III trials evaluating [99mTc]tilmanocept and vital blue dye for identiﬁcation of
sentinel lymph nodes in clinically node-negative cutaneous melanoma. Ann Surg
Oncol 2013;20(2):680–8. http://dx.doi.org/10.1245/s10434-012-2612-z [Epub 2012
Oct 3. PubMed PMID: 23054107; PubMed Central PMCID: PMC3560941].
[54] Marcinow AM, Hall N, Byrum E, Teknos TN, Old MO, Agrawal A. Use of a novel
receptor-targeted (CD206) radiotracer, 99mTc-tilmanocept, and SPECT/CT for
sentinel lymph node detection in oral cavity squamous cell carcinoma: initial
institutional report in an ongoing phase 3 study. JAMA Otolaryngol Head Neck
Surg 2013;139(9):895–902. http://dx.doi.org/10.1001/jamaoto.2013.4239 [PubMed
PMID: 24051744; PubMed Central PMCID: PMC4301415].
[55] Wallace AM, Hoh CK, Limmer KK, Darrah DD, Schulteis G, Vera DR. Sentinel lymph
node accumulation of Lymphoseek and Tc-99 m-sulfur colloid using a "2-day" pro-
tocol. Nucl Med Biol 2009;36(6):687–92. http://dx.doi.org/10.1016/j.nucmedbio.
2009.04.007 [PubMed PMID: 19647175; PubMed Central PMCID: PMC4201841].
[56] Wallace AM, Hoh CK, Darrah DD, Schulteis G, Vera DR. Sentinel lymph node
mapping of breast cancer via intradermal administration of Lymphoseek. Nucl
Med Biol 2007;34(7):849–53 [Epub 2007 Aug 9. PubMed PMID: 17921035;
PubMed Central PMCID: PMC4189800].
[57] de Paulis T. Drug evaluation: Lymphoseek — Neoprobe's sentinel lymph node im-
aging agent for use in cancer patients. Curr Opin Investig Drugs 2006;7(12):
1100–7 [Review. PubMed PMID: 17209528].
[58] Wallace AM, Hoh CK, Ellner SJ, Darrah DD, Schulteis G, Vera DR. Lymphoseek: a
molecular imaging agent for melanoma sentinel lymph node mapping. Ann Surg
Oncol 2007;14(2):913–21 [Epub 2006 Dec 5. PubMed PMID: 17146742].
[59] Wallace AM, Ellner SJ, Méndez J, Hoh CK, Salem CE, Bosch CM, et al. Minimally in-
vasive sentinel lymph node mapping of the pig colon with Lymphoseek. Surgery
2006;139(2):217–23 [PubMed PMID: 16455331].
[60] Agrawal A, Civantos FJ, Brumund KT, Chepeha DB, Hall NC, Carroll WR, et al. [(99m)
Tc]tilmanocept accurately detects sentinel lymphnodes and predicts node pathology
status in patients with oral squamous cell carcinoma of the head and neck: results of
a phase III multi-institutional Trial. Ann Surg Oncol 2015;22(11):3708–15 [Epub
ahead of print, PubMed PMID: 25670018].
[61] Laoui D, Movahedi K, Van Overmeire E, Van den Bossche J, Schouppe E, Mommer C,
et al. Tumor-associated macrophages in breast cancer: distinct subsets, distinct func-
tions. Int J Dev Biol 2011;55(7-9):861–7. http://dx.doi.org/10.1387/ijdb.113371dl.
[62] Lanciotti M, Masieri L, Raspollini MR, Minervini A, Mari A, Comito G, et al. The role
of M1 and M2 macrophages in prostate cancer in relation to extracapsular tumor
extension and biochemical recurrence after radical prostatectomy. Biomed Res
Int 2014. http://dx.doi.org/10.1155/2014/486798.[63] Zhang W, Zhu XD, Sun HC, Xiong YC, Zhuang PY, Xu HX, et al. Depletion of tumor-
associated macrophages enhances the effect of sorafenib in metastatic liver cancer
models by antimetastatic and antiangiogenic effects. Clin Cancer Res 2010;16(13):
3420–30. http://dx.doi.org/10.1158/1078-0432.CCR-09-2904.
[64] Hussein Mahmoud R. Tumor-associated macrophages and melanoma
tumourigenesis: integrating the complexity. Int J Exp Pathol 2006;87(3):163–76.
http://dx.doi.org/10.1111/j.1365-2613.2006.00478.x.
[65] Ding H, Cai J, Mao M, Fang Y, Huang Z, Jia J, et al. Tumor-associated macrophages
induce lymphangiogenesis in cervical cancer via interactions with tumor cells.
APMIS 2014;122(11):1059–69. http://dx.doi.org/10.1111/apm.12257.
[66] Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. N Engl J Med 2010;362:
875–85. http://dx.doi.org/10.1056/NEJMoa0905680.
[67] Huysentruyt LC, McGrath MS. The role of macrophages in the development and
progression of AIDS-related non-Hodgkin lymphoma. J Leukoc Biol 2010;87(4):
627–32. http://dx.doi.org/10.1189/jlb.0809564.
[68] Ribatti D, Vacca A. The role of monocytes-macrophages in vasculogenesis in
multiple myeloma. Leukemia 2009;23:1535–6. http://dx.doi.org/10.1038/leu.
2009.55.
[69] Fujiwara T, Fukushi J, Yamamoto S, Matsumoto Y, Setsu N, Oda Y, et al. Macrophage
inﬁltration predicts a poor prognosis for human ewing sarcoma. Am J Pathol 2011;
179(3):1157–70. http://dx.doi.org/10.1016/j.ajpath.2011.05.034.
[70] Ong SM, Tan YC, Beretta O, Jiang D, Weap WH, Tai JJ, et al. Macrophages in human
colorectal cancer are pro-inﬂammatory and prime T cells towards an anti-tumour
type-1 inﬂammatory response. Eur J Immunol 2012;42(1):89–100. http://dx.doi.
org/10.1002/eji.201141825.
[71] Kumar A, Herbein G. The macrophage: a therapeutic target in HIV-1 infection. Mol
Cell Ther 2014;2:10. http://dx.doi.org/10.1186/2052-8425-2-10.
[72] Kinne RW, Bräuer R, Stuhlmüller B, Palombo-Kinne E, Burmester GR. Macrophages in
rheumatoid arthritis. Arthritis Res 2000;2(3):189–202. http://dx.doi.org/10.1186/
ar86.
[73] Podinovskaia M, Lee W, Caldwell S, Russel DG. Infection of macrophages with My-
cobacterium tuberculosis induces global modiﬁcations to phagosomal function. Cell
Microbiol 2013;15(6):843–59. http://dx.doi.org/10.1111/cmi.12092.
[74] Vogel DYS, Vereyken EJF, Glim JE, Heijnen PDAM, Moeton M, van der Valk P, et al.
Macrophages in inﬂammatory multiple sclerosis lesions have an intermediate acti-
vation status. J Neuroinﬂammation 2013;10:35.
[75] BrückW, Sommermeier N, BergmannM, Zettl U, Geobel HH, Kertzschmar HA, et al.
Macrophages in multiple sclerosis. Immunobiology 1996;195(4-5):588–600.
[76] Orme J, Mohan C. Macrophage subpopulations in systemic lupus erythematosus.
Discov Med 2012;13(169):151–8 [PMID: 22369974].
[77] Li Y, Lee PY, Reeves WH. Monocyte and macrophage abnormalities in systemic
lupus erythematosus. Arch Immunol Ther Exp (Warsz) 2010;58(5):355–64.
http://dx.doi.org/10.1007/s00005-010-0093-y.
[78] Gate D, Rezai-Zadeh K, Jodry D, Tentsendorj A, Town T.Macrophages in Alzheimer’s
disease: the-blood-borne identity. J Neural Transm 2010;117(8):961–70. http://dx.
doi.org/10.1007/s00702-010-0422-7.
[79] Olefsky JM, Glass CK. Macrophages, inﬂammation, and insulin resistance. Annu Rev
Physiol 2010;72:219–46. http://dx.doi.org/10.1146/annurev-physiol-021909-135846.
[80] Perry VH. Innate Inﬂammation in Parkinson’s Disease. Cold Spring Harb Perspect
Med 2012. http://dx.doi.org/10.1011/cshperpect.a009373.
[81] Su X, Federoff HJ. Immune responses in Parkinson’s disease: interplay between
central and peripheral immune systems. Biomed Res Int 2014. http://dx.doi.org/
10.1155/2014/275178.
[82] Liu G, Fiala M, Mizwicki MT, Sayre J, Magpantay L, Siani A, et al. Neuronal phagocy-
tosis by inﬂammatory macrophages in ALS spinal cord: inhibition of inﬂammation
by resolving D1. Am J Neurodegener Dis 2012;1(1):60–74.
[83] GravesMC, FialaM, Dinglasan LA, Liu NQ, Sayre J, Chiappelli F, et al. Inﬂammation in
amyotrophic lateral sclerosis spinal cord and brain is mediated by activatedmacro-
phages, mast cells and T cells. Amyotroph Lateral Scler Other Motor Neuron Disord
2004;5(4):213–9 [PMID: 15799549].
[84] Li J, Hsu HC, Mountz JD. Managing macrophages in rheumatoid arthritis by reform
or removal. Curr Rheumatol Rep 2012;14(5):445–54. http://dx.doi.org/10.1007/
s11926-012-0272-4.
[85] Krown SE, Lee JY, Dittmer DP, AIDS Malignancy Consortium. More on HIV-
associated Kaposi's sarcoma. N Engl J Med 2008;358(5):535–6 [author reply 536.
PMID: 18234764].
[86] Maskew M, Fox MP, van Cutsem G, Chu K, Macphail P, Boulle A, et al. Treatment re-
sponse andmortality among patients starting antiretroviral therapywith andwithout
Kaposi sarcoma: a cohort study. PLoS One 2013;8(6):e64392 [PMID: 23755122].
[87] Nasti G, Talamini R, Antinori A,Martellotta F, Jacchetti G, Chiodo F, et al. AIDS-related
Kaposi's Sarcoma: evaluation of potential new prognostic factors and assessment of
theAIDS Clinical Trial Group Staging System in the Haart Era—the Italian Cooperative
Group on AIDS and Tumors and the Italian Cohort of Patients Naive From
Antiretrovirals. J Clin Oncol 2003;21(15):2876–82 [PMID: 12885804].
[88] Uldrick TS, Whitby D. Update on KSHV epidemiology, Kaposi sarcoma pathogenesis,
and treatment of Kaposi sarcoma. Cancer Lett 2011;305(2):150–62 [PMID: 21377267].
[89] Maurer T, Ponte M, Leslie K. HIV-associated Kaposi's sarcoma with a high CD4
count and a low viral load. N Engl J Med 2007;357(13):1352–3 [PMID: 17898112].
[90] Ma Y, Pope RM. The role of macrophages in rheumatoid arthritis. Curr Pharm Des
2005;11(5):569–80 [PMID: 15720276].
[91] Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al.
Increased unrecognized coronary heart disease and sudden deaths in rheumatoid
arthritis: a population-based cohort study. Arthritis Rheum 2005;52(2):402–11
[PMID: 15693010].
[92] Carmona L, Cross M, Williams B, Lassere M, March L. Rheumatoid arthritis. Best
Pract Res Clin Rheumatol 2010;24(6):733–45 [PMID: 21665122].
225F.O. Cope et al. / Nuclear Medicine and Biology 43 (2016) 215–225[93] Oliver JE, Silman AJ. Why are women predisposed to autoimmune rheumatic
diseases? Arthritis Res Ther 2009;11(5):252 [PMID: 19863777].
[94] Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates
of the prevalence of arthritis and other rheumatic conditions in the United States.
Part I. Arthritis Rheum 2008;58(1):15–25 [18163481].
[95] Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376(9746):
1094–108 [PMID: 20870100].
[96] Hootman JM, Helmick CG. Projections of US prevalence of arthritis and associated
activity limitations. Arthritis Rheum 2006;54:226–9 [PMID: 16385518].
[97] Raza K, Falciani F, Curnow SJ, Ross EJ, Lee CY, Akbar AN, et al. Early rheumatoid
arthritis is characterized by a distinct and transient synovial ﬂuid cytokine proﬁle
of T cell and stromal cell origin. Arthritis Res Ther 2005;7(4):R784–95 [PMID:
15987480].
[98] Olszewski WL, Pazdur J, Kubasiewicz E, Zaleska M, Cooke CJ, Miller NE. Lymph
draining from foot joints in rheumatoid arthritis provides insight into local cyto-
kine and chemokine production and transport to lymph nodes. Arthritis Rheum
2001;44(3):541–9 [PMID: 11263768].
[99] Meyer PW, Hodkinson B, Ally M, Musenge E, Wadee AA, Fickl H, et al. Circulating
cytokine proﬁles and their relationships with autoantibodies, acute phase reac-
tants, and disease activity in patients with rheumatoid arthritis. Mediators Inﬂamm
2010;2010:158514 [PMID: 21437211].
[100] Leizer T, Cebon J, Layton JE, Hamilton JA. Cytokine regulation of colony-stimulating
factor production in cultured human synovial ﬁbroblasts: I. Induction of GM-CSF
and G-CSF production by interleukin-1 and tumor necrosis factor. Blood 1990;
76(10):1989–96 [PMID: 1700731].
[101] Westra J, Doornbos-van der Meer B, de Boer P, van Leeuwen MA, van Rijswijk MH,
Limburg PC. Strong inhibition of TNF-alpha production and inhibition of IL-8 and
COX-2 mRNA expression in monocyte-derived macrophages by RWJ 67657, a
p38 mitogen-activated protein kinase (MAPK) inhibitor. Arthritis Res Ther 2004;
6(4):R384–92 [PMID: 15225374].
[102] Kraan MC, Reece RJ, Smeets TJ, Veale DJ, Emery P, Tak PP. Comparison of synovial
tissues from the knee joints and the small joints of rheumatoid arthritis patients:
Implications for pathogenesis and evaluation of treatment. Arthritis Rheum 2002;
46(8):2034–8 [PMID: 12209505].
[103] Kennedy A, Fearon U, Veale DJ, Godson C. Macrophages in synovial inﬂammation.
Front Immunol 2011;2:52 [PMID: 22566842].
[104] Bresnihan B. Pathogenesis of joint damage in rheumatoid arthritis. J Rheumatol
1999;26(3):717–9 [PMID: 10090189].
[105] Mulherin D, Fitzgerald O, Bresnihan B. Synovial tissue macrophage populations and
articular damage in rheumatoid arthritis. Arthritis Rheum 1996;39(1):115–24
[PMID: 8546720].
[106] Deane KD, Norris JM, Holers VM. Preclinical rheumatoid arthritis: identiﬁcation,
evaluation, and future directions for investigation. Rheum Dis Clin North Am
2010;36(2):213–41 [PMID: 20510231].
[107] El-Gabalawy H. The preclinical stages of RA: lessons from human studies and ani-
mal models. Best Pract Res Clin Rheumatol 2009;23(1):49–58 [PMID: 19233045].
[108] Kraan MC, Versendaal H, Jonker M, Bresnihan B, Post WJ, t Hart BA, et al. Asymp-
tomatic synovitis precedes clinically manifest arthritis. Arthritis Rheum 1998;
41(8):1481–8 [PMID: 9704648].
[109] Demoruelle MK, Deane KD, Holers VM. When and where does inﬂammation
begin in rheumatoid arthritis? Curr Opin Rheumatol 2014;26(1):64–71
[PMID: 24247116].
[110] Azad AK, RajaramMV, Schlesinger LS. Exploitation of the macrophage mannose re-
ceptor (CD206) in infectious disease diagnostics and therapeutics. J Cytol Mol Biol
2014;1(1) [pii: 1000003. PMID: 24672807].
[111] Schlesinger LS. Macrophage phagocytosis of virulent but not attenuated strains of
Mycobacterium tuberculosis is mediated by mannose receptors in addition to com-
plement receptors. J Immunol 1993;150(7):2920–30 [PMID: 8454864].
[112] D'Addio SM, Baldassano S, Shi L, Cheung L, Adamson DH, BruzekM, et al. Optimiza-
tion of cell receptor-speciﬁc targeting through multivalent surface decoration of
polymeric nanocarriers. J Control Release 2013;168:41–9 [PMID: 23419950].
[113] Kang PB, Azad AK, Torrelles JB, Kaufman TM, Beharka A, Tibesar E, et al. The
human macrophage mannose receptor directs Mycobacterium tuberculosis
lipoarabinomannan-mediated phagosome biogenesis. J Exp Med 2005;
202(7):987–99 [PMID: 16203868].
[114] Clemens DL, Horwitz MA. Characterization of the Mycobacterium tuberculosis
phagosome and evidence that phagosomal maturation is inhibited. J Exp Med
1995;181(1):257–70 [PMID: 7807006].
[115] Sturgill-Koszycki S, Schaible UE, Russell DG. Mycobacterium-containing
phagosomes are accessible to early endosomes and reﬂect a transitionalstate in normal phagosome biogenesis. EMBO J 1996;15(24):6960–8 [PMID:
9003772].
[116] Guirado E, Schlesinger LS, Kaplan G. Macrophages in tuberculosis: friend or foe.
Semin Immunopathol 2013;35(5):563–83. http://dx.doi.org/10.1007/s00281-
013-0388-2 [PMID: 23864058].
[117] Russell DG, Cardona PJ, Kim MJ, Allain S, Altare F. Foamy macrophages and the
progression of the human tuberculosis granuloma. Nat Immunol 2009;10(9):
943–8. http://dx.doi.org/10.1038/ni.1781 [Epub 2009 Aug 19. PMID: 19692995].
[118] Peyron P, Vaubourgeix J, Poquet Y, Levillain F, Botanch C, Bardou F, et al. Foamy
macrophages from tuberculous patients' granulomas constitute a nutrient-rich
reservoir for M. tuberculosis persistence. PLoS Pathog 2008;4(11):e1000204.
http://dx.doi.org/10.1371/journal.ppat.1000204 [PMID: 19002241].
[119] Kim MJ, Wainwright HC, Locketz M, Bekker LG, Walther GB, Dittrich C, et al.
Caseation of human tuberculosis granulomas correlates with elevated host lipid
metabolism. EMBO Mol Med 2010;2(7):258–74. http://dx.doi.org/10.1002/
emmm.201000079 [PMID: 20597103].
[120] Ehlers S, Schaible UE. The granuloma in tuberculosis: dynamics of a host–pathogen
collusion. Front Immunol 2013;3:411. http://dx.doi.org/10.3389/ﬁmmu.2012.
00411 [PMID: 23308075].
[121] Fan J, Watanabe T. Inﬂammatory reactions in the pathogenesis of atherosclerosis.
J Atheroscler Thromb 2003;10(2):63–71 [PMID: 12740479].
[122] Libby P. Inﬂammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012;
32(9):2045–51 [PMID: 22895665].
[123] Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Nerem RM. The pathogenesis of
atherosclerosis: an overview. Clin Cardiol 1991;14(2 Suppl 1):I1–I16 [PMID: 2044253].
[124] Liang M, Puri A, Devlin G. The vulnerable plaque: the real villain in acute coronary
syndromes. Open Cardiovasc Med J 2011;5:123–9 [PMID: 21673834].
[125] Kullo IJ, Edwards WD, Schwartz RS. Vulnerable plaque: pathobiology and clinical
implications. Ann Intern Med 1998;129(12):1050–60 [PMID: 9867761].
[126] Benedek T, Jako B, Benedek I. Plaque quantiﬁcation by coronary CT and intravascu-
lar ultrasound identiﬁes a low CT density core as a marker of plaque instability in
acute coronary syndromes. Int Heart J 2014;55(1):22–8 [PMID: 24463925].
[127] Zhou J, ChewM, Ravn HB, Falk E. Plaque pathology and coronary thrombosis in the
pathogenesis of acute coronary syndromes. Scand J Clin Lab Invest Suppl 1999;230:
3–11 [PMID: 10389196].
[128] Falk E, Nakano M, Bentzon JF, Finn AV, Virmani R. Update on acute coronary syn-
dromes: the pathologists' view. Eur Heart J 2013;34(10):719–28 [PMID: 23242196].
[129] Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance.
Nat Rev Immunol 2013;13(10):709–21 [PMID: 23995626].
[130] Bekkering S, Quintin J, Joosten LA, van der Meer JW, NeteaMG, Riksen NP. Oxidized
low-density lipoprotein induces long-term proinﬂammatory cytokine production
and foam cell formation via epigenetic reprogramming of monocytes. Arterioscler
Thromb Vasc Biol 2014;34(8):1731–8 [pii: ATVBAHA.114.303887. [Epub ahead of
print] PMID: 24903093].
[131] Sakakura K, NakanoM, Otsuka F, Ladich E, Kolodgie FD, Virmani R. Pathophysiology
of atherosclerosis plaque progression. Heart Lung Circ 2013;22(6):399–411 [PMID:
23541627].
[132] Narula J, Nakano M, Virmani R, Kolodgie FD, Petersen R, Newcomb R, et al. Histo-
pathologic characteristics of atherosclerotic coronary disease and implications of
the ﬁndings for the invasive and noninvasive detection of vulnerable plaques.
J Am Coll Cardiol 2013;61(10):1041–51 [PMID: 23473409].
[133] Tahara N, Mukherjee J, de Haas HJ, Petrov AD, Tawakol A, Haider N, et al. 2- deoxy-
2-[18 F]ﬂuoro-D-mannose positron emission tomography imaging in atherosclero-
sis. Nat Med 2014;20:215–9 [PMID: 24412923].
[134] Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time
for reassessment. F1000Prime Rep 2014;6:13 [eCollection 2014. PMID: 24669294].
[135] Zizzo G, Hilliard BA, Monestier M, Cohen PL. Efﬁcient clearance of early apoptotic
cells by human macrophages requires M2c polarization and MerTK induction.
J Immunol 2012;189(7):3508–20 [PMID: 22942426].
[136] Thorp E, Cui D, Schrijvers DM, Kuriakose G, Tabas I. Mertk receptor mutation re-
duces efferocytosis efﬁciency and promotes apoptotic cell accumulation and
plaque necrosis in atherosclerotic lesions of apoe-/- mice. Arterioscler Thromb
Vasc Biol 2008;28(8):1421–8 [PMID: 18451332].
[137] Weiss RA. How does HIV cause AIDS? Science 1993;260(5112):1273–9 [PMID:
8493571].
[138] Torres RA, Barr M. Impact of combination therapy for HIV infection on inpatient
census. N Engl J Med 1997;336(21):1531–2 [PMID: 9157292].
[139] Zanni MV, Abbara S, Lo J, Wai B, Hark D, Marmarelis E, et al. Increased coronary
atherosclerotic plaque vulnerability by coronary computed tomography angiogra-
phy in HIV-infected men. AIDS 2013;27(8):1263–72 [PMID: 23324657].
